The Food and Drug Administration’s upcoming guidance on a regulatory pathway for biosimilars may provide clarity on the naming convention for these complex generics. The agency is expected to soon issue more guidance, said Dr. Janet Woodcock, head of the FDA’s Center for Drug Evaluation and Research, at a Bloomberg LP conference on Feb. 14.

Read more…